Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 475 of 496 entries
View as:

A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03290703 Org: User:
Start: 04/18/17 End: 10/25/18 Due: 10/25/19

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00058552 Org: User:
Start: 05/31/03 End: 07/31/04 Due: 07/31/05

A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane

Phase: N/A Priority: Normal
NCT ID: NCT00097487 Org: User:
Start: 11/30/00 End: 09/30/04 Due: 09/30/05

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05646836 Org: User:
Start: 03/21/23 End: 09/30/26 Due: 09/30/27

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00927589 Org: User:
Start: 07/31/09 End: 02/28/13 Due: 02/28/14

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02569801 Org: User:
Start: 12/04/15 End: 02/28/20 Due: 02/28/21

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

Phase: N/A Priority: Normal
NCT ID: NCT00312026 Org: User:
Start: 03/30/06 End: 11/28/06 Due: 11/28/07

A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies

Phase: N/A Priority: Normal
NCT ID: NCT00096980 Org: User:
Start: 02/28/01 End: 05/31/04 Due: 05/31/05

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00854126 Org: User:
Start: 05/31/09 End: 07/31/12 Due: 07/31/13

A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00087529 Org: User:
Start: 06/30/04 End: - Due: -

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02311894 Org: User:
Start: 03/31/15 End: 11/08/17 Due: 11/08/18

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT06693908 Org: User:
Start: 03/31/25 End: 05/06/26 Due: 05/06/27

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02640092 Org: User:
Start: 12/23/15 End: 06/11/19 Due: 06/11/20

A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

Phase: N/A Priority: Normal
NCT ID: NCT00497497 Org: User:
Start: 10/31/07 End: 09/30/10 Due: 09/30/11

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Phase: N/A Priority: Normal
NCT ID: NCT01609140 Org: User:
Start: 05/31/12 End: 07/31/13 Due: 07/31/14

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02655614 Org: User:
Start: 05/31/16 End: 03/16/20 Due: 03/16/21

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Phase: N/A Priority: Normal
NCT ID: NCT00739661 Org: User:
Start: 12/31/08 End: 11/30/10 Due: 11/30/11

A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00997919 Org: User:
Start: 10/31/09 End: 02/28/10 Due: 02/28/11

A Study of Patients With HER2-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00105456 Org: User:
Start: 03/31/03 End: 05/31/09 Due: 05/31/10

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01209130 Org: User:
Start: 10/31/10 End: 03/31/15 Due: 03/31/16

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03563716 Org: User:
Start: 08/10/18 End: 08/31/25 Due: 08/31/26

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00679211 Org: User:
Start: 08/31/08 End: 04/30/11 Due: 04/30/12

Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02699710 Org: User:
Start: 09/03/15 End: 05/26/16 Due: 05/26/17

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00287716 Org: User:
Start: 07/14/06 End: 11/10/08 Due: 11/10/09

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Phase: N/A Priority: Normal
NCT ID: NCT04195958 Org: User:
Start: 11/30/20 End: 10/18/21 Due: 10/18/22